Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology Forms Alliance with World Leading Translational Research Centres

Published: Monday, January 21, 2013
Last Updated: Monday, January 21, 2013
Bookmark and Share
The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network.

MRC Technology, a technology transfer charity and company, announces it is one of six of the world’s top translational health research centres  that have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. 

The founding organizations are: 

The Centre for Drug Research and Development (CDRD), Canada
Lead Discovery Center (LDC), Germany
The Scripps Research Institute, Scripps Florida, United States
The Centre for Drug Design and Discovery (CD3), KU Leuven R&D, Belgium
Medical Research Council Technology, United Kingdom
Cancer Research Technology, United Kingdom

All member organizations are fully-integrated translational centres capable of professionally advancing drug discovery projects along the value chain from idea to drug candidate with proof-of-concept.  Together, they represent close to 400 experienced drug developers collaborating with tens of thousands of academic scientists around the globe on over 165 highly innovative therapeutic projects targeting significant unmet medical needs. For the biopharmaceutical industry, they represent a major source of innovation. Numerous alliances with many of the industry’s leading global companies have been established to develop resulting drug candidates further and ultimately make them available to patients.

Through this Alliance, member organizations will collaborate on mutually-beneficial projects, share best practices, expertise and resources, and develop common standards and performance measurements – ultimately working together to improve the conversion of global early-stage technology into much needed therapies.

Karimah Es Sabar, President and CEO of CDRD commented, “We see a multitude of translational research initiatives around the world, but until now, these have for the most part, worked in isolation of one another. This Alliance will be a powerful vehicle in bringing such organizations together, leveraging one another’s strengths, and ultimately making for a much more effective global translational research environment.”  

Mike Johnson, MRC Technology’s Director of Corporate Partnerships said: “The shared objectives between MRC Technology and the other members of the Alliance make collaborating rather than competing the obvious way forward. I hope that by working together we can move research from the lab bench to the patient faster and more effectively.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
Charities Pledge to Inject Millions to Jump Start Drug Development for Brain Diseases
MRC Technology to lead Neurodegeneration Medicines Acceleration Programme to uncover promising drugs in pharma libraries.
Tuesday, November 18, 2014
MRC Technology Negotiates License with Bio-Techne for MRC’s GOPAL Protein Synthesis Technology
Technology enables production of ubiquitin reagents and other proteins for use in drug discovery.
Wednesday, August 27, 2014
MRC Technology, AstraZeneca Renew Target Discovery Collaboration
Initiative brings together global expertise to share compound libraries and streamline drug discovery.
Thursday, July 03, 2014
MRC Technology Sells its MCRs Programme to Pfizer
Small molecules developed in collaboration with Queen Mary University of London.
Thursday, June 19, 2014
MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
Initiative brings together global expertise to streamline drug discovery.
Wednesday, May 14, 2014
£3m Dementia Consortium Launched
New Consortium aims to boost dementia drug discovery by uniting charity, academic and private sectors in search for new treatments.
Wednesday, December 11, 2013
MRC Technology and Oxford University Collaborate
The project will screen TRESK potassium channel activators involved in migraine pain control.
Thursday, November 14, 2013
MRC Technology and Renishaw Diagnostics Collaborate
Initiative combines expertise to accelerate clinical diagnostic screening.
Thursday, October 03, 2013
MRC Technology Launches Small Molecule Compound Library Access Scheme
Subset of compound library to be made available to academic researchers free of charge.
Thursday, September 20, 2012
Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!